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 Introduction 
 To reach the general market, a medical device must fi rst pass a set 
of standards and regulations designated by its class. 1 Devices are 
classifi ed as Class I, II, or III based on risk of the device and the 
level of control necessary to assure safety and effi  cacy ( Figure  1 A ). 
Class I devices are considered low-risk and are subjected to 
general controls alone, while Class III devices, which includes 
most implants, are considered high-risk and are subjected to the 
most complete and stringent standards. 2 Class III devices are 
typically granted an initial Investigational Device Exemption 
(IDE) allowing use of the device exclusively in a FDA-regulated 
clinical trial to collect necessary safety and effi  cacy data prior to 
market application. 3 
 Class III devices can use a number of pathways to reach the 
market, with the premarket approval (PMA) pathway being most 
common. 4 A notable alternative mechanism is the Humanitarian 
Use Device (HUD) program, created for devices intended for 
patients with rare life-threatening diseases or conditions. Treading 
through the conventional marketing pathways is a costly process, 
especially when taking into account the clinical trials run to gather 
device effi  cacy data. Consequently, inventors are unlikely to pursue 
projects that can solve or alleviate rare diseases and conditions 
since such a solution typically does not translate to a large profi t. As 
a result, the FDA created the HUD pathway to encourage inventors 
to develop potential devices designed to fi ght rare diseases. Th e 
HUD pathway allows the applicant to develop a medical device 
without the requirement for effi  cacy data, and the process is 
notably expedited, with a decision given to an applicant within 
45 calendar days. To acquire HUD designation, the inventor must 
provide the FDA supporting documentation demonstrating the 
rarity of a disease, which must aff ect fewer than 4,000 patients in 
the United States per year. Additionally, the inventor must include 
a comprehensive description of the device and its intended use, 
with scientifi c rationale behind the device. Aft er the applicant is 
granted HUD designation and IDE regulations are satisfi ed, the 
device is eligible for marketing through the Humanitarian Device 
Exemption (HDE) pathway, an application similar to the PMA 
(but much less onerous) in that safety data must be provided, but 
notably exempt from providing eff ectiveness data. 
 Although the FDA readily provides guidance for device 
regulation, notably through the Pre-Submission Program, it is 
understandable that regulatory pathways authored to fi t medical 
devices of all kinds are nevertheless complicated to apply, 
especially with new and rapidly evolving technology such as 
three-dimensional (3D) printing. 5 
 Introduction to 3D printing 
 Traditional manufacturing, also called subtractive manufacturing, 
starts with a block of material and removes excess through methods 
such as milling and machining until a fi nal product is attained. 6 
3D printing, also referred to as additive manufacturing or rapid 
prototyping, is a process whereby a 3D model of a product is 
electronically sliced into individual layers and material is deposited 
in a layer-wise fashion until the fi nal product is built ( Figure  2 ) . 
Th is ability to “build something out of nothing” holds several 
notable advantages, most notable being the capability to build 
complex and protean geometries not possible with traditional 
subtractive manufacturing. 6 3D printing technology has rapidly 
penetrated the medical device industry over the past several years, 
with applications such as patient-specifi c craniofacial implants for 
reconstruction of the skull and facial skeleton, titanium hip and 
mandibular prostheses, and scaff olding for tissue engineering. 7–9 
Innovative groups have harnessed the technology to create 
devices with unique composition, structure, and customizability. 
However, the unique structures and applications aff orded by 3D 
printing have introduced unique regulatory challenges, which 
we will illustrate by discussing our experience with our group’s 
3D-printed bioresorbable implantable device used in treatment 
of life-threatening disease. 10 
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 Abstract 
 Three-dimensional (3D) printing, or additive manufacturing, technology has rapidly penetrated the medical device industry over the 
past several years, and innovative groups have harnessed it to create devices with unique composition, structure, and customizability. 
These distinctive capabilities afforded by 3D printing have introduced new regulatory challenges. The customizability of 3D-printed 
devices introduces new complexities when drafting a design control model for FDA consideration of market approval. The customiz-
ability and unique build processes of 3D-printed medical devices pose unique challenges in meeting regulatory standards related to 
the manufacturing quality assurance. Consistent material powder properties and optimal printing parameters such as build orientation 
and laser power must be addressed and communicated to the FDA to ensure a quality build. Postprinting considerations unique to 
3D-printed devices, such as cleaning, fi nishing and sterilization are also discussed. In this manuscript we illustrate how such regulatory 
hurdles can be navigated by discussing our experience with our group’s 3D-printed bioresorbable implantable device. Clin Trans Sci 
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 Device Background 
 Tracheobronchomalacia (TBM) is a pediatric condition of 
excessive dynamic collapse of the primary airways during 
respiration. In rare severe cases, standard therapies fail with 
high rates of treatment-associated and disease-associated 
morbidity and mortality. 11 Our multidisciplinary team designed 
an archetype device, termed the tracheobronchial splint (TBS), 
which uses patient-specifi c computer-aided design (CAD) to 
create a custom device to treat this condition. 10 Patient-specifi c 
devices are designed by imaging-based CAD and manufactured 
from a bioresorbable material using a 3D 
printer ( Figure  3 A ). Each device is designed 
using patient anatomy for design input, a 
design process which is consistent with the 
philosophy of personalized medicine and 
a hallmark feature of 3D-printed medical 
devices. 
 As a class III device aimed towards 
treating a rare disease process, HUD 
designation with subsequent HDE 
application was the most appropriate 
regulatory pathway for the TBS. An HUD 
application containing a description of 
the intended use of the device, supporting 
documentation of the rarity of TBM, and 
preclinical results was approved in 2012. Our 
group is currently in the midst of the IDE 
approval process, with an FDA-regulated 
clinical trial forthcoming to further defi ne 
the safety profi le of the device. 
 Preprinting Considerations 
 Design control 
 As a requirement for IDE approval, the 
design control model was implemented in 
the creation of the TBS. Design control is a 
system of device development that promotes 
identification of potential design flaws, 
creation of multiple design concepts, and 
verifi cation and validation of design effi  cacy 
via repeated design review ( Figure  1 B ). 12 Th e 
design control model classically consists of 
the following interrelated categories: user 
needs, design inputs, design processes, 
design outputs, and validation ( Table  1 ). 
Th ough tedious, design control is benefi cial 
as potentially costly design errors are 
discerned early in the design process. 
 User needs for the TBS were addressed by 
Zopf et al., who listed qualitative objectives 
for an ideal device to treat TBM ( Table  2 A ). 13 
User needs were subsequently translated 
into distinct design input requirements 
( Table  2 B ). In a traditional model, device 
designs are created to set specifi cations and 
a design process is developed to fulfi ll the 
specifi cations. If multiple design variations 
exist, design processes equal to the number 
of variants are typically created and 
validated. Standardizing the design process 
for 3D-printed devices is uniquely challenging in that these 
devices allow many design parameters to be customized based 
on user needs resulting in a potentially infi nite number of design 
variants. As such, it becomes necessary to incorporate design 
verifi cation and design validation steps into the overall design 
and manufacturing process for personalized 3D-printed devices. 
 Th e TBS includes ten bounded physical parameters utilized as 
design inputs, each measured to the patient’s anatomy ( Table  2 B ). 
Th is degree of freedom allows over 450 million unique design 
variations which rendered traditional design process verifi cation 
  
 Figure 1.  Classifi cation of medical devices and the design control process for device design. (A) Classifi cation 
of medical devices is based on the degree of risk to the patient. Greater risk necessitates a greater degree of 
regulatory control for device market approval. (B) The design control model is suggested by the FDA for medical 
device development. Adapted from U.S. Food and Drug Administration, "Design Control Guidance for Medical 
Device Manufacturers", Guidance for Industry and Food and Drug Administration Staff, issued March 11, 1997. 
  
 Figure 2.  Overview of 3D printing of medical devices. (A) Medical device design is created to user needs with 
computer-aided design (CAD) software and exported as stereolithography (.STL) fi le. (B) Device .STL is “sliced” 
in layer-wise fashion (left) and laid out on virtual build platform (right) using 3D printer software. (C) Build is 
exported to 3D printer and assembled by depositing material “slice-by-slice” until fi nal model is created. In our 
process (selective laser sintering), a base substrate powder is spread evenly and a laser melts the powder in the 
shape of the “slice.” The build platform then descends, a new layer of powder is spread, and the next “slice” is 
melted. (D) For many 3D printing processes, the completed device is buried within a basin of build substrate 
or powder. The completed device is sifted out of the substrate and extracted. (E) The completed device is then 
cleaned to remove residual substrate, often by air-jet or waterjet blasting. (F) The fi nal cleaned medical device 
is then ready for sterilization. 
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impossible, leading us to develop standard operating procedures 
(SOPs) for our design process. First, we obtain computed 
tomography (CT) imaging of the patient’s airway using fi xed, 
specifi c imaging parameters. We generate a 3D model of the 
patient’s airway using Mimics (Materialise Inc., Leuven, Belgium) 
and measure the aff ected anatomy using MEDCAD functions to 
generate the ten design inputs. Design inputs are entered into a 
custom MATLAB (Mathworks Inc., Natick, MA, USA) code that 
generates the design output as a stereolithography (.STL) fi le. 
 Design verification is performed by virtually fitting the 
generated device model over a 3D model of the patient’s airway, 
to ensure its dimensional properties allow an adequate fi t. To date, 
this process has been suffi  cient for design verifi cation for the FDA 
as long as it is performed with each design iteration. 
 Class III implantable devices typically require both pre-
clinical laboratory and animal model testing to validate 
device performance and establish a safety 
profile. We developed a porcine animal 
model of TBM for validation of clinical 
performance requirements of the TBS. 13 
Functional requirements are validated aft er 
manufacture via testing of the device on 
an MTS RT/30 Alliance machine under 
compression, three-point bending, and 
open wedge displacement to mimic the  in 
vivo environmental forces exerted on the 
splint. 14 We test each splint design iteration 
to validate that functional performance fi ts 
within the criteria stated within  Table  2 A , as 
the design output varies with each patient. 
 Conventional design validation of 
mechanical performance on the TBS 
has been cost and labor intensive and 
is unsustainable when scaling to mass 
production. Finite element analysis (FEA) 
is a process by which a virtual mathematical 
model is created to predict mechanical 
performance of a virtual model of a device. 15 
FEA has been investigated as a surrogate for 
design validation processes and is in many 
ways ideally suited for 3D-printed devices as 
design outputs already exist as a virtual model. 16–18 Additionally, 
FEA programs can model future states of a device, such as growing 
tissues or material degradation. For the TBS, an FEA model was 
designed that simulates a bronchus that grows as the patient ages 
( Figure  3 B ). Modifi cations to the model that incorporate material 
degradation into the model are in development. 
 FEA is an attractive alternative to conventional mechanical 
testing as it avoids sacrifice of manufactured devices that 
conventional testing requires and can be easily applied to a 
wide variety of design variations. However, FEA models require 
resource investment for model validation to allow meaningful 
interpretation of FEA model results. 16–18 Additionally, regulatory 
approval of FEA as a replacement for conventional design 
validation of devices has not been explicitly expressed by the 
FDA. Nevertheless, FEA can be a useful mechanism for assessing 
device design performance of 3D-printed devices. 
  
 Figure 3.  Design process of the tracheobronchial splint. (A) Patients undergo computed tomography (CT) imaging 
of the airway to characterize the location and severity of disease. (B) DICOM images from the CT scan are used to 
generate a 3D model of the patient’s airway within Mimics (Materialise) on which measurements are performed 
to generate device design inputs. (C) Design inputs are fed into a proprietary MATLAB (Mathworks) code which 
generates a series of 2D .TIFF images (representative image left). These are imported into Mimics and used to 
generate a .STL of the device design (right). (D) Verifi cation of performance requirements is done by virtually 
fi tting the 3D model of the device over the 3D model of the patient’s airway to ensure proper fi t. (E) Verifi cation 
of functional requirements is done by converting the .STL of the device into a volumetric mesh and performing 
fi nite element analysis (FEA) within ANSYS (Ansys Inc) to ensure proper mechanical behaviors. 
Term Defi nition 
User needs Qualitative requirements deemed necessary for successful treatment of an illness or condition. 
Design input Requirements of a device that are used as a basis for device design. Typically grouped into functional 
requirements, performance requirements, and interface requirements. 
Functional  requirements What the device does, focusing on the operational capabilities. 
Performance  requirements How much or how well the device must perform, addressing issues such as speed, strength, response 
times, accuracy, limits of operation, etc .
Interface requirements Characteristics of the device which are critical to compatibility with external systems .
Design process The process of translating a design concept into a functioning prototype. 
Design output The results of a design effort at each phase of the design process and at the end of the total design effort. 
Verifi cation The process of checking at each stage of the design process whether the design output meets input 
 requirements. If the data from the output is within the acceptable range established by the design input, 
then the design concept is verifi ed. 
Validation Establishing by objective evidence that fi nal device specifi cations meet user needs and intended use. 
 Table 1.  Defi nitions of design control model. Adapted from U.S. Food and Drug Administration, “Design Control Guidance for Medical Device Manufacturers”, Guidance for 
Industry and Food and Drug Administration Staff, Issued March 11, 1997. 
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A. User needs and requirements for TBS 
 Clinical user needs 
1.  Must maintain support for a critical 24-month duration and subsequently degrade. 
2.  Must predictably and effectively exert a balanced radial force in the axial plane restoring the native lumen size and resisting external 
compression yet allowing for internal expansion during growth and transverse plane movement during cervical motion. 
3.  Must be placed external to airway to leave mucociliary architecture unaltered. 
4.  Must be straightforward to place the device onto the affected airway segment (i.e., low user complexity). 
 Performance requirements 
1.  Must be customized to the patient’s specifi c defect size and location to 0.5 mm accuracy. 
 Functional requirements 
1.  Must exhibit maximum displacement of less than 10% of initial splint diameter under 50N compressive load. 
2.  Must exhibit displacement greater than 20% of initial splint diameter, but less than 50% of initial splint diameter under 50N three-
point bending load. 
3.  Must exhibit a displacement greater than 20% of initial splint diameter under 15N opening angle load. 
 Biomaterial requirements 
1.  Must not cause tissue reaction or remodeling (i.e. non-erosive), local or systemic toxicity. 
2.  Must exhibit a degradation profi le which ensures structural integrity for a critical 24-month duration and be fully bioresorbable. 
B. Design process for TBS 
 Generating design inputs 
1.  Thin-cut computed tomography (CT) images of patient’s airway are obtained in inspiration and expiration. 
2.  DICOM images of CT scan are input into Mimics and used to generate 3D model of patient’s airway using threshold function. 
3.  Centerline function is performed on airway model, and measurements performed to generate TBS design inputs. 
4.  Design inputs: X diameter, Y diameter, wall thickness, bellow height, bellow wave shape, bellow periodicity, suture hole thickness, 
open wedge angle, length, spiral to open wedge angle. 
 Design process 
1.  Design inputs are fed into proprietary MATLAB code which generates series of 2D .TIFF slices. 
2.  TIFF slices input into Mimics to generate 3D model (.STL) of TBS design. 
 Design output verifi cation 
1.  3D model of TBS virtually fi t over 3D model of patient’s airway to ensure proper fi t within Mimics. 
2.  Finite Element Analysis (FEA) of design output in compression, three-point bending, and open angle displacement meets user needs criteria. 
C. Device validation for TBS 
 Clinical validation 
1.  Manufactured device based on design output alleviates symptoms of TBM in preclinical animal model. 
2.  Manufactured device based on design output does not demonstrate airway growth restriction in preclinical animal model. 
 Mechanical validation 
1.  Bench mechanical testing of manufactured device based on design output in compression, three-point bending, and open angle 
displacement meets user needs criteria. 
 Biomaterial validation 
1.  Device manufacture material composition meets ISO 10993 standards. 
2.  Manufactured device based produces no adverse tissue reaction in preclinical animal model. 
 Table 2.  Design control process for the 3D-printed tracheobronchial splint. 
bioresorbability profi le, while HA was added as a fl owing agent 
to improve powder distribution during printing. Virgin PCL 
powder is cryogenically milled to a median particle size of 40–60 
 μ m, promoting a higher resolution build with more accurate 
physical dimensions and uniform density. 20 To ensure regulatory 
quality requirements, the powder is tested aft er milling using 
standardized procedures to ensure a uniform particle size and 
polydispersity index. Th ese procedures were deemed appropriate 
by the FDA. 
 While many of the Quality Assurance (QA) processes for 
3D-printed devices are identical to those that have been used in 
industry for decades, a unique manufacturing process allowable 
by 3D printing is “recycling” of manufacturing substrate from 
one build to the next. It has been previously demonstrated that 
 Printing Considerations 
 Raw materials 
 FDA Quality System (QS) Regulation/Medical Device Good 
Manufacturing Practices for industry manufactured devices 
should be implemented throughout the manufacturing process 
of 3D-printed implantable devices, beginning with the substrate 
used for manufacture. 19 Source materials for 3D printing should 
be evaluated as they are for any other manufacturing process, with 
appropriate quality control to ensure homogeneous and traceable 
manufacturing substrate. 
 For our device, we use a mix of 95% polycaprolactone 
(PCL) with 5% hydroxyapatite (HA). PCL was utilized as 
our manufacturing substrate due to its biocompatibility and 
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for many 3D printing processes, the use of recycled substrate may 
result in superior quality of manufactured devices. 21,22 However, 
there have been concerns expressed by the FDA and others 
that recycling introduces potential for material contamination, 
diminishing performance of recycled materials over time, and 
additional complexities with material traceability. Several methods 
have been proposed method to mitigate these issues, including 
use of defi ned refresh rate of recycled-to-virgin powder with a 
controlled number of allowed cycles and a set expiration date or 
routine retesting of recycled materials. 21,23 It is yet to be determined 
whether routine recycling of materials for 3D-printed implantable 
devices will be acceptable by the FDA. Further work to defi ne the 
potential for material contamination and further shelf life testing 
of 3D printing biomaterials are necessary to better characterize 
these risks, and in-depth study of the chosen raw materials will be 
necessary for regulatory approval of 3D-printed implants. 
 Technical considerations 
 A number of 3D printing parameters have been shown to 
significantly impact the physical characteristics of the final 
manufactured device, such as laser beam energy density, scanning 
speed, deposition velocity, and humidity within the build 
environment. 1 As such, quality measures to ensure consistency 
between builds are needed and necessary to document for 
regulatory purposes. 
 Previous work has demonstrated that 3D-printed devices can 
have only 15% tensile strength in the build direction, especially 
in laser sinter systems. 24,25 Th is is thought to be due to anisotropy 
introduced between print layers and is especially applicable to 
devices with complex structures or devices used in load-bearing 
regions of the body. Additionally, in certain 3D printing processes 
the position of the device layout within the build platform can 
result in device variations. 23,26 Much like a batch of cookies baking 
in an oven, “hot spots” and “cold spots” exist and devices built in 
unfavorable positions such as the platform edges are at increased 
risk of warping. Characterization of the mechanical properties of 
the device along specifi c z-axis orientations and characterization 
of the build platform environment with standardized constructs 
(informally referred to as “coupons”), as described by Jande et al., 
have been proposed as a mechanism to test consistency of 3D 
printing builds. 27 
 To decrease the risk of build inaccuracies, the FDA will 
require that all printing parameters and processes for the TBS 
be included in the IDE application. We developed a fi xed range 
of build parameters for the TBS to ensure consistency of laser 
sintering of PCL based on prior work by our group. These 
include laser power of 4 Watts, bed temperature of 50–56°C, 
laser scanning speed of 1000–1500 mm/sec, and scan spacing of 
0.15-0.20 mm. 28–32 Th e optimal orientation (longitudinal along 
the z-axis) and position on the build platform were determined 
with mechanical testing and standardized for the IDE application 
so that the z-axis is orientated along the length of the device. 
Additionally, as recommended by Jande et al, standardized porous 
cylindrical constructs are manufactured and tested as coupons 
with each build to detect any signifi cant build variations. 
 Postmanufacture quality assurance 
 Despite appropriate quality controls for printing processes, 
variations in manufactured devices may still occur. Th ere have 
been a variety of techniques employed by various authors to 
ensure the fi nal product is representative of the design output. 
Th ese include surface laser scanning, micro-CT and various 
printer monitoring strategies. 33 Th e specifi c techniques chosen for 
postmanufacture quality assurance testing are oft en determined 
by the material utilized and the size and shape of the device. 
For devices with complex internal structures, postmanufacture 
device “cutups” may be required to assess the fi delity of the entire 
manufactured device. As of yet, standard guidance for post-
manufacture QA of 3D-printed devices has not been published. 
For the TBS, we utilize caliper measurements of wall thickness, 
inner diameter, and length, and are currently implementing 
micro-CT processes to assess device geometry and density. 
Th ese processes were deemed suffi  cient by the FDA for the IDE 
application. 
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 Table 3.  FDA recommended initial ISO 10993 evaluation tests for implant devices; X = evaluation tests for consideration; O = additional evaluation tests should be 
addressed in the submission, either by inclusion of the testing or a rationale for its omission. Note: Tissue includes tissue fl uids and subcutaneous space. Adapted from 
US Department of Health and Human Services, “Use of International Standard ISO-10993, Biological Evaluation of Medical Devices Part 1: Evaluation and Testing. Draft 
Guidance for Industry and Food and Drug Administration Staff”, Draft Guidance, Issued April 23, 2013. 
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 Postprinting Considerations 
 Cleaning and fi nishing 
 Cleaning of postmanufacture 3D-printed devices is necessary 
regardless of the 3D printing technique used. Th e method of 
cleaning varies based on the printing process utilized, from 
removal of support material to removal of residual monomers. 
Certain techniques may require additional fi nishing processes 
such as tumblers or sandblasting. Extraction of residual material 
by the cleaning process should be complete, which may be 
diffi  cult in 3D-printed devices that employ porous surfaces or 
complex internal structures. Th is is of particular relevance if 
support materials or fl owing agents are not biocompatible, and 
may present a hurdle to regulatory approval if cleaning processes 
cannot be demonstrated to be suffi  cient. 
 Validation that fi nishing processes do not alter the overall 
structure or mechanical properties of the manufactured device 
beyond design input requirements will likely be necessary, but 
has not been explicitly expressed by the FDA to date. 34 Th is is of 
particular concern given that microporosity from the printing 
process may serve as critical crack initiation sites if fi nishing 
processes are too aggressive. Validation of device geometry and 
mechanical performances postfi nishing processes can serve as a 
mechanism to overcome this regulatory barrier. 
 In our laser-sintering process, devices are cleaned via air-
blasting in a contained environment to remove gross excess 
powder, followed by sonication in ethanol to remove residual 
debris. All devices were mechanically tested aft er cleaning to 
ensure the cleaning process did not signifi cantly alter device 
functional performance, and this was deemed appropriate for 
incorporation in the IDE application. We do not employ any 
fi nishing techniques and as such did not have to validate device 
postfi nishing processes. 
 Biocompatibility 
 Th e International Organization of Standards (ISO) has published 
a set of standards for evaluating the biocompatibility of materials 
used in the manufacture of medical devices, collectively termed ISO 
10993. 35 Th e FDA has adopted these standards and enforces them 
for Class III devices. 36 Th e device structure, material composition, 
and intended use ultimately determine which aspects of ISO 10993 
are necessary for regulatory approval ( Table  3 ). 
 Unique factors arise when attempting to apply these standards 
to 3D-printed implants. Raw materials may be altered by the 3D 
printing process (such as cross-linking or melting) which can 
potentially alter the material’s properties.  37 As such, testing of raw 
materials may be insuffi  cient. Additives during the manufacturing 
process (such as support materials, fl owing agents, or binding 
materials) may also need to be tested sure ensure they are removed 
completely during cleaning processes or that they are ISO 10993 
compliant if still present within the fi nal manufactured device. 
For biodegradable implants, it is important to fully characterize 
the degradation profi le using  in vitro and  in vivo degradation 
studies. Degradation testing may also be necessary for shelf life 
testing of fi nal manufactured devices. 
 For the TBS, the FDA recommended that degradation testing 
be performed on bounded extremes of the device design inputs, 
incorporating the largest and smallest potential devices. Th is 
narrowed our design variations to be tested from greater than 
64 million to 115. Accelerated  in vitro degradation testing, where 
devices were submerged in a basic solution in an incubator, was 
explicitly requested by the FDA to characterize the mechanical 
performance of the TBS over 9 months. Th is time frame mimicked 
the time-critical period the device must be intact for treating 
tracheobronchomalacia.Real-time  in vivo degradation testing and 
stress testing of bounded device designs of up to 36 months was 
requested to be run concurrent with the clinical trial. 
 Sterilization 
 Sterility is fundamental to minimizing risk of infection with 
implantable medical devices. Given the numerous materials 
utilized in 3D printing, a variety of sterilization processes 
can potentially be employed. Th e sterilization process may be 
determined by device-structure, compatibility between the process 
and device material, or process availability. Sterility assurance 
level (SAL) is the probability of a single unit being nonsterile 
aft er it has been subjected to sterilization. Material compatibilities 
may require deviation from standardized sterilization protocols, 
which makes validation of SAL essential. For example, the melting 
point of PCL is 60°C, which lies below the standard temperature 
for most conventional sterilization processes, including steam 
sterilization and ethylene oxide (EtO) gas sterilization. We utilized 
a modifi ed EtO gas sterilization protocol for sterilization of the 
TBS with a lower gas temperature (49°C). 
 Regardless of the sterilization process, 3D-printed implants 
require the same validation of SAL as any other medical implant 
and results must be presented to the FDA as part of the marketing 
application. 37 Th e battery of validation tests required depends on 
the materials used and the sterilization method, and will likely 
require consultation from the FDA on a case-by-case basis. Classic 
sterility validation requires all design iterations of a device to 
undergo validation testing. Similar to device design validation, 
sterility validation of 3D-printed implants is not feasible given the 
infi nite potential design variations. Th e FDA requested that sterility 
validation be performed on bounded design variables of the TBS 
in a similar model to degradation testing. Additionally, the FDA 
requested that minimal requirements to demonstrate device safety 
performed, which for the TBS included  in vitro cytotoxicity studies 
under ISO 10993–5 requirements. Validation will be performed 
using a battery of testing, including biologic indicator testing, 
pyrogenicity and endotoxin testing, and residual EtO gas testing. 
Th e FDA also stated that they will consider sterilization from 
previously implanted patients. Further input from the FDA will be 
required to develop consensus strategies for sterility validation of 
3D-printed medical devices that are highly variable in structure. 
 Conclusions 
 Th e expansion of 3D printing technology has produced innovative 
medical devices with novel composition and structure. Th e ability 
to rapidly alter size and shape of these devices to meet specifi c 
patient needs allows for rapidly producible “custom” devices 
but introduces unique regulatory challenges for device design 
development, manufacturing, biocompatibility, and sterilization. 
Applying the same design and quality control strategies utilized 
in standard manufacturing methods with 3D printing will result 
in a controlled output and consistent production of devices. 
However, given the “custom” nature of many 3D-printed implants, 
further guidance is necessary to establish which quality control 
measures will necessary for each device iteration. Th e maturation 
of 3D printing within the biomedical industry will ultimately be 
dependent on the ongoing evolution and synthesis of regulation 
and technology. 
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